Sandoz Launches High-Concentration Adalimumab In Europe

Plans To ‘Progressively’ Roll Out 100mg/ml Version Of Hyrimoz Biosimilar To Humira

 
• By Dave Wallace

Sandoz has launched the high-concentration version of its Hyrimoz adalimumab biosimilar rival to Humira in Europe.

High low 3D words
Sandoz will be offering a 100mg/ml high-concentration formulation of Hyrimoz alongside the existing 50mg/ml low-concentration version • Source: Shutterstock

More from Biosimilars

More from Products